Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Dow
AstraZeneca
Harvard Business School
McKinsey
Colorcon
Teva
Farmers Insurance

Generated: September 22, 2018

DrugPatentWatch Database Preview

ABLAVAR Drug Profile

« Back to Dashboard

Which patents cover Ablavar, and when can generic versions of Ablavar launch?

Ablavar is a drug marketed by Lantheus Medcl and is included in one NDA. There is one patent protecting this drug.

The generic ingredient in ABLAVAR is gadofosveset trisodium. Additional details are available on the gadofosveset trisodium profile page.

Summary for ABLAVAR
Drug patent expirations by year for ABLAVAR
Generic Entry Opportunity Date for ABLAVAR
Generic Entry Date for ABLAVAR*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for ABLAVAR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-001 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Lantheus Medcl ABLAVAR gadofosveset trisodium SOLUTION;INTRAVENOUS 021711-002 Dec 22, 2008 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for ABLAVAR

Supplementary Protection Certificates for ABLAVAR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2007003,C0806968 Lithuania ➤ Try a Free Trial PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REGISTRATION NO/DATE: EU/1/05/313/001, 2005 10 05 EU/1/05/313/002, 2005 10 05 EU/1/05/313/003, 2005 10 05 EU/1/05/313/004, 2005 10 05 EU/1/05/313/005, 2005 10 05 EU/1/05/313/006, 2006 10 05 EU/1/05/313/007, 2005 10 05 EU/1/05/313/008, 2005 10 05 EU/1/05/313/00 2005100
0253 Netherlands ➤ Try a Free Trial 300253, 20160116, EXPIRES: 20201002
C0028 France ➤ Try a Free Trial PRODUCT NAME: GADOFOSVESET TRISODIQUE; REGISTRATION NO/DATE: EU/1/05/313/001-009 20051003
2007 00016 Denmark ➤ Try a Free Trial
0806968/01 Switzerland ➤ Try a Free Trial FORMER REPRESENTANTIVE: BOVARD AG PATENTANWAELTE, CH
2007003 Lithuania ➤ Try a Free Trial PRODUCT NAME: GADOFOSVESETUM TRINATRICUM; REG NO/DATE: EU/1/05/313/001-009 20051005
C 037/2006 Ireland ➤ Try a Free Trial SPC 037/2006: 20070528, EXPIRES: 20201002
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Dow
AstraZeneca
Harvard Business School
McKinsey
Colorcon
Teva
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.